1. Home
  2. TECX vs DIAX Comparison

TECX vs DIAX Comparison

Compare TECX & DIAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • DIAX
  • Stock Information
  • Founded
  • TECX 2019
  • DIAX 2005
  • Country
  • TECX United States
  • DIAX United States
  • Employees
  • TECX N/A
  • DIAX N/A
  • Industry
  • TECX
  • DIAX Finance Companies
  • Sector
  • TECX
  • DIAX Finance
  • Exchange
  • TECX Nasdaq
  • DIAX Nasdaq
  • Market Cap
  • TECX 334.4M
  • DIAX 527.7M
  • IPO Year
  • TECX 2018
  • DIAX N/A
  • Fundamental
  • Price
  • TECX $22.19
  • DIAX $14.34
  • Analyst Decision
  • TECX Buy
  • DIAX
  • Analyst Count
  • TECX 5
  • DIAX 0
  • Target Price
  • TECX $79.20
  • DIAX N/A
  • AVG Volume (30 Days)
  • TECX 237.5K
  • DIAX 96.6K
  • Earning Date
  • TECX 08-13-2025
  • DIAX 01-01-0001
  • Dividend Yield
  • TECX N/A
  • DIAX 7.93%
  • EPS Growth
  • TECX N/A
  • DIAX N/A
  • EPS
  • TECX N/A
  • DIAX N/A
  • Revenue
  • TECX N/A
  • DIAX N/A
  • Revenue This Year
  • TECX N/A
  • DIAX N/A
  • Revenue Next Year
  • TECX N/A
  • DIAX N/A
  • P/E Ratio
  • TECX N/A
  • DIAX N/A
  • Revenue Growth
  • TECX N/A
  • DIAX N/A
  • 52 Week Low
  • TECX $13.70
  • DIAX $12.80
  • 52 Week High
  • TECX $61.07
  • DIAX $15.12
  • Technical
  • Relative Strength Index (RSI)
  • TECX 54.15
  • DIAX 57.09
  • Support Level
  • TECX $20.39
  • DIAX $13.63
  • Resistance Level
  • TECX $22.01
  • DIAX $14.57
  • Average True Range (ATR)
  • TECX 1.18
  • DIAX 0.14
  • MACD
  • TECX 0.15
  • DIAX 0.02
  • Stochastic Oscillator
  • TECX 92.82
  • DIAX 75.27

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About DIAX Nuveen Dow 30SM Dynamic Overwrite Fund of Beneficial Interest

Nuveen Dow 30sm Dynamic Overwrite Fund is a non-diversified closed-end management investment company. Its investment objective is to seek attractive total return with less volatility than the Dow Jones Industrial Average by investing in an equity portfolio that seeks to substantially replicate the price movements of the DJIA, as well as selling call options on 35%-75% of the notional value of the Fund's equity portfolio.

Share on Social Networks: